BBNX Stock — Beta Bionics, Inc. Common Stock

Beta Bionics, Inc. Common Stock (BBNX)

Updated October 16, 2026.

BBNX is a Stock. Total return is -30.8% over the past 1.7 years, 59.4 points behind SPY at 28.6%.

Beta Bionics is a commercial-stage medical device company developing automated insulin delivery systems for people with diabetes, including its FDA-cleared iLet Bionic Pancreas and pipeline products like a patch-based pump and bihormonal delivery system. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage medical device innovation in the diabetes management space, though investors should recognize the risks typical of pre-profitability healthcare companies.

BBNX performance versus SPY

Price and return data through 2026-10-16.

Total return is -30.8% over the past 1.7 years, 59.4 points behind SPY at 28.6%. Over the past year its total return — price change plus distributions reinvested — is -20.7%. Its deepest 1-year drawdown was 72.3%.

BBNX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/30/2025

Distribution frequency

None

Last close

$16.35 (as of 2026-10-16)

Market cap

$882,020,550

Average volume

660830.0

Payout ratio

0.0%

EPS

$-1.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BBNX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 72.3%.

Who may consider BBNX — and who may not

It is a weaker fit for investors who need monthly cash flow (BBNX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BBNX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions